69-LB: A Wearable Microneedle Array Sensor Shows High Correlation between Dermal Glucose and Venous Blood Glucose
| العنوان: | 69-LB: A Wearable Microneedle Array Sensor Shows High Correlation between Dermal Glucose and Venous Blood Glucose |
|---|---|
| المؤلفون: | Thomas A. Peyser, Pradnya P. Samant, Rayhan A. Lal, Joshua Ray Windmiller, Mark P. Christiansen, Jared Rylan Tangney, Naresh C. Bhavaraju, Alan Campbell, Sirilak Sattayasamitsathit |
| المصدر: | Diabetes. 69 |
| بيانات النشر: | American Diabetes Association, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Continuous measurement, business.industry, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Venous blood, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Lag time, Internal Medicine, Medicine, Glucose monitors, Linear correlation, business, Biomedical engineering |
| الوصف: | Objective: Current continuous glucose monitors (CGM) measure glucose in the subcutaneous interstitial fluid (ISF). Previous ex vivo research with hypodermic needles has shown that glucose in the dermal ISF is highly correlated to venous glucose with little or no lag time. However, this methodology is not viable for continuous measurement. In this study, we have developed and tested a wearable microneedle array sensor for continuous in situ measurement of glucose in the dermal ISF. A dermal CGM could be applied without an introducer needle and without pain during application. Methods: In this study the microneedle array sensor was tested against venous glucose measured every 15 minutes from a YSI analyzer in 8-hour sessions over 2 days (Phase One) and 5-7 days (Phase Two). Results: Five participants without diabetes and 10 participants with diabetes were recruited for phase One and 10 participants with diabetes were recruited for phase Two. A high degree of linear correlation (R2 ≥ 0 .90) between the microneedle array measured dermal ISF glucose and venous glucose was observed. The figure shows the linear correlation (A) and temporal profile (B) for one microneedle array sensor over 8 hours. Conclusions: A wearable microneedle array measuring dermal ISF glucose can accurately track glucose values. The study demonstrated early human feasibility of a CGM based on microneedle sensing of dermal ISF. Disclosure P.P. Samant: Employee; Self; Biolinq. M.P. Christiansen: Research Support; Self; Abbott, Ascensia Diabetes Care, Biolinq, Dexcom, Inc., Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Novo Nordisk A/S, Sanofi-Aventis, Senseonics, ViroMed Laboratories, Xeris Pharmaceuticals, Inc. S. Sattayasamitsathit: None. A. Campbell: None. T.A. Peyser: Consultant; Self; Insulet Corporation. Employee; Self; Biolinq. J.R. Windmiller: Employee; Self; Biolinq. J.R. Tangney: Board Member; Self; Biolinq. R. Lal: Consultant; Self; Abbott, Biolinq. N.C. Bhavaraju: Employee; Self; Biolinq. |
| تدمد: | 1939-327X 0012-1797 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::b918b9766af75a3c12c7c9a740f9ae7bTest https://doi.org/10.2337/db20-69-lbTest |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........b918b9766af75a3c12c7c9a740f9ae7b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1939327X 00121797 |
|---|